ChiCTR2300074661 版本V1.0 版本创建时间2023/08/11 15:59:54 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300074661 

最近更新日期:

Date of Last Refreshed on:

2023-08-11 15:59:49 

注册时间:

Date of Registration:

2023-08-11 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

关于非小细胞肺癌新辅助治疗后机器人手术的回顾性研究

Public title:

Retrospective Comparison of Robotic- and Video-assisted Thoracic Surgery after Neoadjuvant Therapy in Non-small Cell Lung Cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

机器人辅助胸腔镜手术在新辅助非小细胞肺癌患者手术安全性、可行性的研究

Scientific title:

Safety and Efficacy of Rabotic-assisted Thoracic Surgery in Non-Small Cell Lung Cancer after Neoadjuvant Therapy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李泓基 

研究负责人:

钟文昭 

Applicant:

Hong-Ji Li 

Study leader:

Wen-Zhao Zhong 

申请注册联系人电话:

Applicant telephone:

+86 138 0276 7497

研究负责人电话:

Study leader's telephone:

+86 136 0977 7314

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hjli16@fudan.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

syzhongwenzhao@mail.scut.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市中山二路106号

研究负责人通讯地址:

广东省广州市中山二路106号

Applicant address:

106 Zhongshan er road, Guangzhou, Guangdong 510080, P. R. China

Study leader's address:

106 Zhongshan er road, Guangzhou, Guangdong 510080, P. R. China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广东省人民医院,广东省肺癌研究所

Applicant's institution:

Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

研究负责人所在单位:

广东省人民医院,广东省肺癌研究所

Affiliation of the Leader:

Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY2023-134-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广东省人民医院伦理委员会

Name of the ethic committee:

the ethics and scientific committees of Guangdong Provincial People’s Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-03-23 00:00:00

伦理委员会联系人:

谭虹

Contact Name of the ethic committee:

Hong Tan

伦理委员会联系地址:

广东省广州市中山二路106号

Contact Address of the ethic committee:

106 Zhongshan er road, Guangzhou, Guangdong 510080, P. R. China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 8382 7812

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广东省人民医院(广东省医学科学院)

Primary sponsor:

Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences)

研究实施负责(组长)单位地址:

广东省人民医院(广东省医学科学院)

Primary sponsor's address:

106 Zhongshan er road, Guangzhou, Guangdong 510080, P. R. China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省人民医院

具体地址:

广东省广州市中山二路106号

Institution
hospital:

Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences)

Address:

106 Zhongshan er road, Guangzhou, Guangdong 510080, P. R. China

经费或物资来源:

该研究由国家自然科学基金会及广东省人民医院高水平医院建设计划资助。

Source(s) of funding:

This study was supported by National Natural Science Foundation (grant 82241235 to W.-Z.Z.) and High-level Hospital Construction Project (grant DFJH201910 to B.-Y.J. and grant DFJH201801 to W.-Z.Z.).

Target disease:

Non-small cell lung cancer

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

比较机器人辅助胸腔金手术与传统胸腔镜手术在新辅助治疗后非小细胞肺癌患者中的安全性和有效性  

Objectives of Study:

The aim of this study was to compare RATS and video-assisted thoracic surgery (VATS) after neoadjuvant treatment

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)18-80岁 2)符合NSCLC疾病的诊断标准,临床分期为IB-IIIB期: 3)接受新辅助治疗 4)新辅助治疗后接受手术

Inclusion criteria

1) 18-80 years old. 2) Pathological diagnosis of NSCLC, pathological staging of IB-IIIB(N2) (8th TNM Stage system). 3) Receiving neoadjuvant therapy 4) Receiving surgery after neoadjuvant therapy

排除标准:

1)临床数据无法获得 2)新辅助后行楔形切除或肺段切除术

Exclusion criteria:

1) Without available clinical information. 2) Receiving wedge resection or segmentectomy.

研究实施时间:

Study execute time:

From 2023-04-01 00:00:00 To 2023-08-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-01 00:00:00 To 2023-07-12 00:00:00  

干预措施:

Interventions:

组别:

根据患者是否接受机器人胸腔镜手术分组

样本量:

50

Group:

Grouping based on whether patients have undergone robotic-assisted thoracoscopic surgery

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China 

Province:

Guangdong 

City:

 

单位(医院):

广东省人民医院(广东省医学科学院) 

单位级别:

三甲 

Institution
hospital:

Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences)

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

R0切除率

指标类型:

主要指标

Outcome:

R0 resection rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术时间

指标类型:

主要指标

Outcome:

Operation time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中出血量

指标类型:

主要指标

Outcome:

Estimated blood loss

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中转开胸率

指标类型:

次要指标

Outcome:

The rate of conversion to thoracotomy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

淋巴结切除数量

指标类型:

附加指标

Outcome:

The number of lymph nodes yeilded

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.medresman.org.cn/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.medresman.org.cn/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

None

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-08-11 15:59:49